Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14414260 | 0.94 | CTSK (0.51) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL542675 | 0.94 | OPRM1 (0.55) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL7917248 | 0.94 | BTK (0.54) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL12794288 | 0.93 | CTSK (0.52) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL12794285 | 0.93 | CTSK (0.52) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL13036669 | 0.91 | CTSK (0.49) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL4715249 | 0.91 | CTSK (0.51) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL16055278 | 0.91 | CTSK (0.51) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL803320 | 0.91 | CTSK (0.58) | CTSKOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL16604751 | 0.91 | CTSK (0.48) | CTSKOPRM1OPRD1OPRK1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-1636216-B1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-07-21 | — | — | EP | disclosed |
| US-7741341-B2 | Benzimidazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-22 | — | — | US | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-1636216-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101553-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
| EP-1314733-A1 | Indole-2-carboxamides as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | CTSK 481/4885OPRM1 860/4885OPRD1 801/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CTSK 2059/4885OPRM1 4750/4885OPRD1 4708/4885 |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | F12, F11, F5 | CTSK 96/4885OPRM1 2097/4885OPRD1 1933/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CTSK 2059/4885OPRM1 4750/4885OPRD1 4708/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | CTSK 496/4885OPRM1 812/4885OPRD1 736/4885 |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | F12, F5, F2 | CTSK 526/4885OPRM1 797/4885OPRD1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.